Abstract

Vinay Kumar^1*, Pawan Prajapati¹, Gauri Goyal¹, Virendra Pratap Singh Rathore² and Ashutosh Mishra³

DOI : http://dx.doi.org/10.13005/ojc/400224

Psoriasis, impacting 2-3% of the population, poses a chronic challenge. Conventional treatments having limited effectiveness and adverse effects; recent immunological insights foster targeted therapies, while herbal medications gain attention for safety and accessibility.
The current research aimed to assess the efficacy of Boerhavia diffusa in mitigating psoriasis induced by imiquimod in mice. Study induced psoriasis in albino mice using 5% imiquimod cream for 5 days, then treated with Boerhavia diffusa (1% and 3%) and Tazarotene (0.1%). Parameters were assessed in the study viz. PASI score, spleen weight/body weight ratio, serum inflammatory markers (IL-17, IL-23, and TNF-α), and skin histopathology. Mice treated with imiquimod exhibited noteworthy elevations in PASI score, spleen weight/body weight ratio, and serum inflammatory markers, which were effectively suppressed by Boerhavia diffusa and Tazarotene applications. Topically application of Boerhavia diffusa significantly ameliorated psoriasis, suggesting it as a promising, well-tolerated alternative to enhance the quality of life for affected individuals.

Boerhavia diffusa; Inflammatory markers; Molecular targets; PASI; Psoriasis

[ View HTML Full Text]